NCT07551674 Effects of Action Observation and Metaphorical Imagery in Pelvic Floor Muscle Training for Geriatric Urinary Incontinence
| NCT ID | NCT07551674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fenerbahce University |
| Condition | Urinary Continence |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2026-07-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-03-19 with a primary completion date of 2026-07-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial investigates the effects of a 12-week Pelvic Floor Muscle Training (PFMT) program applied via Action Observation Therapy (AOT) with metaphorical imagery on urinary incontinence, quality of life, and treatment adherence in geriatric women. The study will be conducted between June 2025 and June 2026 in nursing homes in Istanbul, targeting women aged 65 and older who are diagnosed with stress or stress-predominant mixed urinary incontinence, possess normal cognitive function (Standardized Mini Mental Test score ≥ 24), and walk independently. Eligible participants will be divided into groups, where both will undergo a progressive exercise regimen involving twice-weekly 45-50 minute group sessions that advance from supine positions to standing and jumping movements. However, the AOT study group will uniquely perform these exercises while observing and imagining projected metaphor-themed visuals to enhance motor learning and motivation. Efficacy will be evaluated pre- and post-intervention using various standardized tools, including the Pelvic Floor Distress Inventory-20, a 24-hour pad test, the Incontinence Severity Index, the Movement Imagery Questionnaire-3, and the Incontinence Quality of Life Scale, to comprehensively assess improvements in incontinence severity, functional status, and overall well-being.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with stress or stress-predominant mixed urinary incontinence by a physician * Women aged 65 years and older * Literate in Turkish to understand, interpret, and answer the questionnaires * Scoring 24 or higher on the Mini-Mental State Examination (MMSE) * Able to walk independently without the use of any walking aids (assistive devices) * Having signed the informed consent form Exclusion Criteria: * Received pelvic floor muscle training within the past 6 months * Presence of fecal incontinence * Current genitourinary infection or use of medication for urinary incontinence * History of urinary incontinence surgery or presence of symptomatic pelvic organ prolapse * Presence of neurological, orthopedic, psychiatric, hematological, or cardiovascular conditions that would preclude participation in exercise * Body mass index (BMI) ≥ 25 kg/m² * Hearing or visual impairments that would negatively affect participation * Presence of hematuria, urethral and/or bladder fistula, or a history of pelvic surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07551674 clinical trial?
This trial is open to female participants only, aged 65 Years or older, up to 80 Years, studying Urinary Continence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07551674 currently recruiting?
Yes, NCT07551674 is actively recruiting participants. Contact the research team at arzu.ozdincler@fbu.edu.tr for enrollment information.
Where is the NCT07551674 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07551674 clinical trial?
NCT07551674 is sponsored by Fenerbahce University. The trial plans to enroll 40 participants.